Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, while other regions such as Latin America, Eastern Europe and parts of Asia are expected to have a strong growth. As the pharmaceutical industry continues to evolve, CDMOs will play an increasingly important role in drug development and manufacturing.
Leading pharmaceutical Softgel CDMO, Sofgen Pharmaceuticals, part of Procaps Group, is ideally placed to capitalize on this and other changing demands within the market through its range of Softigel technologies that service different patient and consumer needs and its new Softgel facility in the US.
As Latin America´s largest Softgel CDMO, Sofgen by Procaps Group offers contract manufacturing and development services in Softgel advanced technologies for pharmaceutical companies looking for differentiation, while simultaneously improving efficiency, and gaining access to specialized expertise, and unique technologies for fixed-dose combinations in Softgels, as an example.
Our Softgel facility and Center for Pharmaceutical Excellence located in West Palm Beach, US, specializes in the development and manufacturing of high-end softgel technologies, with expertise in complex oral modalities such as hormonal products and high potency compounds, and other differentiated manufacturing technologies.
Sofgen offers a diverse service portfolio that goes from Research for Advanced Delivery Technologies, End-to-end solutions for Orphan / Fast-track developments, pre-clinical and clinical developments for new Molecular Entities, lab analytical services, all the way to bottling & product inspection services.
Our expansion to the United States provides us with a wider capability to deliver our pharmaceutical products to our strategic partners and ensure the continued quality of their brands which are their most valued assets. The increase in production capacities will provide us with the opportunity to deliver a wider product array as we move even closer to our customers in the North American markets as we implement our ambitious growth plans.
The pharmaceutical industry is moving towards personalized medicine, which involves developing drugs tailored to specific patient needs. CDMOs are also increasingly focused on providing customized drug development and manufacturing services to meet the specific needs of their clients. Sofgen Pharmaceuticals, as an integrated CDMO, iCDMO, is investing in investigating what are these specific needs, so we can integrate our advanced oral technologies and services to tackle in a more direct and specific way those needs.
Through our innovative technologies for oral delivery systems, plus our vast knowledge and expertise of more than 45 years in Softgel development and manufacturing, we offer the flexibility, value, and customization of our partners´ needs, driven by our passion to develop customized products that exceed our customers’ expectations, with a relationship model based on connectivity, trust, and empathy.
Sofgen Pharmaceuticals, your flexible partner for Innovation in Softgel delivery.
[1] IQVIA. Global Use of Medicines 2023 Outlook to 2027. Jan 2023.
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance